DIAGNOS gets regional diabetic-retinopathy screening contract in Mexico
Under the contract, DIAGNOS will provide turnkey screening services for thousands of diabetic patients in Mexico City and the Mexican states of Toluca, Chiapas and San Luis Potosi. Screening will be offered to diabetics affiliated with different Mexican Public Health institutions.
"We are excited to increase our operations in Mexico through this pharmaceutical company and begin screening for diabetic retinopathy,” Guillermo Moreno, director of business development for DIAGNOS, said. “Following the expected success of this project, we intend to expand the scope of services offered through this pharmaceutical company into other cities and regions in Mexico in the same way it has been done in other countries."
Mexico has a population of 132 million, and the International Diabetes Federation said 15 million residents are diabetics — the sixth-largest diabetic population in the world.
Diabetic retinopathy is the most common diabetic eye disease and the leading cause of blindness around the world. It is a treatable disease with a greater treatment success rate in the early stages.
“The large majority of the diabetic population in Mexico does not receive regular screening for diabetic retinopathy (under 5 percent), so we are poised to deliver screening through the use of CARA, our powerful technological solution," Moreno said.